SillaJen, Inc.
Research SillaJen, Inc. (215600.KQ) on Bullrun: market cap KRW 300.66B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker215600.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 300.66B
- Financial periodQ2 2026
- RevenueKRW 2.24B
- Net income-KRW 5.49B
- Free cash flow-KRW 4.38B
- Gross margin73.5%
Valuation Snapshot
latest market cap is KRW 300.66B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 300.66B | n/a | n/a | n/a |
Dividend history
About SillaJen, Inc.
SillaJen, Inc., together with its subsidiaries, engages in developing technologies and products using genetic engineering in South Korea. Its clinical pipeline includes Pexa-Vec, which is in phase 2 clinical trial to treat renal cell carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. The company also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is SillaJen, Inc.'s market cap?
SillaJen, Inc.'s market capitalization is KRW 300.66B.
What does SillaJen, Inc. do?
SillaJen, Inc., together with its subsidiaries, engages in developing technologies and products using genetic engineering in South Korea. Its clinical pipeline includes Pexa-Vec, which is in phase 2 clinical trial to treat renal cell carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. The company also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial. In addition, it operates in biotechnology research industry. SillaJen, Inc.